# Sherene Loi

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/sherene-loi/

## Facts

| Field | Value |
| --- | --- |
| Citations | 81,461 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 128 |
| i10-index | 402 |
| Last Known Institution | The University of Melbourne |
| OpenAlex ID | https://openalex.org/A5010278367 |
| ORCID iD | https://orcid.org/0000-0001-6137-9171 |
| Works | 1,199 |

## Researcher papers

- [The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014](https://scholariq.org/papers/the-evaluation-of-tumor-infiltrating-lymphocytes-tils-in-breast-cancer/)
- [ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer](https://scholariq.org/papers/esmo-clinical-practice-guideline-for-the-diagnosis-staging-and-treatment-of/)
- [Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer](https://scholariq.org/papers/tucatinib-trastuzumab-and-capecitabine-for-her2-positive-metastatic-breast/)
- [Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers](https://scholariq.org/papers/tumor-infiltrating-lymphocytes-and-response-to-neoadjuvant-chemotherapy-with-or/)
- [Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study](https://scholariq.org/papers/pertuzumab-trastuzumab-and-docetaxel-for-her2-positive-metastatic-breast-cancer/)
- [Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors](https://scholariq.org/papers/assessing-tumor-infiltrating-lymphocytes-in-solid-tumors-a-practical-review-for/)
- [Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study](https://scholariq.org/papers/pembrolizumab-monotherapy-for-previously-treated-metastatic-triple-negative/)
- [Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research](https://scholariq.org/papers/assessing-tumor-infiltrating-lymphocytes-in-solid-tumors-a-practical-review-for-2/)
- [Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial](https://scholariq.org/papers/intracranial-efficacy-and-survival-with-tucatinib-plus-trastuzumab-and/)
- [Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial](https://scholariq.org/papers/pembrolizumab-plus-trastuzumab-in-trastuzumab-resistant-advanced-her2-positive/)
- [The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group](https://scholariq.org/papers/the-tale-of-tils-in-breast-cancer-a-report-from-the-international-immuno/)
- [Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative](https://scholariq.org/papers/genomic-and-transcriptomic-analyses-of-breast-cancer-primaries-and-matched/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [The University of Melbourne](https://scholariq.org/institutions/the-university-of-melbourne/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.